Drs. Goeffrey Oxnard and Lauren Ritterhouse consider how next-generation sequencing (NGS) informs treatment of lung cancer patients in providing information on tumor mutational burden, microsatellite instability, unique targetable genomic signatures, as well as novel targets that may be best addressed in a clinical trial.
Video Library —July 18, 2018
Categories:
Interview with the InnovatorsThoracic Oncologist, Dana-Farber Cancer Institute,
Associate Professor of Medicine, Harvard Medical School,
Boston, MA
Associate Professor of Medicine, Harvard Medical School,
Boston, MA
Molecular Pathologist and Co-Director
Molecular Diagnostics and Clinical Genomics Laboratories, University of Chicago
Chicago, IL
Molecular Diagnostics and Clinical Genomics Laboratories, University of Chicago
Chicago, IL
Last modified: August 10, 2023